Researchers find 150 possible inhibitors to fight Nipah virus
A group of scientists from India have used 3D imaging of the Nipah virus to discover potential inhibitors for the disease.
List view / Grid view
A group of scientists from India have used 3D imaging of the Nipah virus to discover potential inhibitors for the disease.
This in-depth focus features articles on identifying new leads for neglected tropical diseases and how to develop novel peptide hits into lead compounds.
Isolated components found in the Saussurea controversa plant have antimicrobial and regenerative properties which could lead to a treatment for bone diseases.
A study using high-throughput screening has revealed some promising compounds that could be used in future cancer treatments.
In a recent study more than half of patients with advanced prostate cancers appear to be strong candidates for targeted cancer therapies.
Drug target identification has a key role in the drug discovery value chain. A critical step in the development of pharmaceuticals is identifying the direct targets of potential drug candidates as well as distinguishing any secondary or off-target effects...
Scientists have equipped a virus that kills carcinoma cells with a protein so it can also target and kill adjacent cells...
In today’s modern world, data is everywhere. This eBook will guide you through the steps of how to achieve more with accurate data.
This whitepaper explains how you can find ways to optimise the holistic preclinical development process...
Researchers report that in preclinical models they can amplify macrophage immune responses against cancer using a self-assembling supramolecule...
Penn study suggests that targeting amyloid fibrils could prevent sexual transmission...
A new study presents an epigenetic drug capable of slowing down cell growth in Mantle Cell Lymphoma (MCL)...
For lead optimisation, target-based assays are still the most affordable means of rapidly performing fast iterations and remain core to screening. However, the desire for biological relevance is driving ongoing growth in cell-based assays.
There are no short-cuts in the complex field of lipidomics, explains Cristina Legido-Quigley, a Principal Investigator in Systems Medicine at Steno Diabetes Center Copenhagen in Denmark and at King’s College London.
This application note discusses how the Alpha SureFire® Ultra™ Multiplex technology provides a phosphoprotein multiplexing detection platform that is truly homogeneous and high throughput.